相关实验视频

Updated: Jan 12, 2026

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

逃离平原:以3D碳酸为基础的Erlotinib生物异构剂作为潜在的抗癌剂

Belén Dávila¹, Pablo Vignolo¹, Ignacio González¹

¹Grupo de Química Orgánica Medicinal, Instituto de Química Biológica, Facultad de Ciencias, Universidad de la República, Montevideo 11400, Uruguay.

|November 3, 2025

概括

基于carborane的新型erlotinib类型显示出针对质母细胞瘤的增强抗癌活性. 化合物17显示出显著的细胞毒性和选择性,具有有前途的安全性和药物动力学特征,需要进一步开发.

科学领域:

药用化学医学化学
药物发现药物发现药物发现
在瘤学瘤学.

背景情况:

药物中的环会导致溶解性差和不稳定.
碳酸为环提供了一个3D,富含的替代品.
探索碳酸作为生物异构剂,以改善药物特性.

研究的目的:

设计和合成Erlotinib的基于carborane的新型类似物.
评估它们的抗癌活性和针对质母细胞瘤的选择性.
研究它们的作用机制和药理动力学特性.

主要方法:

合成的carborane-carborane类比的erlotinib. 这是一个很好的方法.
在体外细胞毒性测定针对质母细胞瘤和星球细胞.
EGFR抑制测定 (野生类型和T790M突变).
分子对接和动力学模拟.
在体内安全性 (LD50) 和艾姆斯测试.
在 silico ADMET 分析和化学稳定性测试.

主要成果:

卡博拉类型在体外比埃洛提尼布更好地改善了生物行为.
副衍生物13和17表现出2.5至12倍以上的细胞毒性.
化合物13和17对质母细胞瘤的选择性比星球细胞高出7倍.
化合物17抑制了野生类型的EGFR (IC50 = 9.23μM) 和EGFR T790M (IC50 = 7.19μM).
化合物17显示出极好的口服安全性 (LD50>2000 mg/kg) 并且没有突变性潜力.
预计16和17的化合物会穿过血脑屏障.

结论:

化合物17是质母细胞瘤治疗的有希望的头.
碳酸的生物异构增强了抗癌疗效和选择性.
需要进一步的研究来阐明化合物17的完整机制,并优化临床转化.

更多相关视频

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Preclinical Assessment of the Bioactivity of the Anticancer Coumarin OT48 by Spheroids, Colony Formation Assays, and Zebrafish Xenografts

Published on: June 26, 2018

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...